McKesson’s Strategic Restructuring and Growth Potential Earns ‘Buy’ Rating from Analyst

Analyst Allen Lutz of Bank of America Securities maintained a Buy rating on McKesson, with a price target of $800.00.

Allen Lutz has given his Buy rating due to a combination of factors that highlight McKesson’s strategic evolution and growth potential. The company has recently announced a restructuring of its reportable segments, which now include North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, and Other. This new structure is designed to provide better transparency and reflects McKesson’s strategic focus on high-growth areas.
McKesson’s emphasis on its Oncology and Multispecialty segment is particularly noteworthy, as it represents a significant portion of the company’s revenue and includes both lower and higher margin businesses. The company’s investments in oncology, such as the acquisition of Florida Cancer Specialists and partnerships with the Sarah Cannon Research Institute, underscore its commitment to this sector. Additionally, the new segment disclosures offer clarity on McKesson’s margin structure, with the specialty segment showing a higher adjusted EBIT margin compared to core distribution. These strategic moves and financial insights contribute to Lutz’s positive outlook on McKesson’s stock.

In another report released on September 17, Evercore ISI also maintained a Buy rating on the stock with a $800.00 price target.